异基因造血干细胞移植后免疫重建的研究
Study of Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
DOI: 10.12677/ACM.2023.13122703, PDF,   
作者: 李玉芳：青海大学临床医学院，青海 西宁
关键词: PD-1；TIM-3；LAG-3；CD47；PD-1； TIM-3； LAG-3； CD47
摘要: 异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation, allo-HSCT)通过移植物抗白血病效应(graft-versus-leukemia, GVL)实现了对血液系统恶性肿瘤的治愈效果，执行GVL的供者T淋巴细胞经历活化扩增及效应的过程后清除白血病细胞，成为中高危血液病有效的治疗手段。T淋巴细胞是发挥移植物抗白血病的主要效应细胞，且在移植后感染、GVHD和复发中发挥重要作用。PD-1、TIM-3、LAG-3、CD47通过不同机制抑制T细胞发挥免疫效应，所以异基因造血干细胞移植后T淋巴细胞及上述免疫检查点的重建规律的研究对于预后有重大意义。
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has achieved curative effects on he-matologic malignancies through graft-versus-leukemia (GVL), and the donor T lymphocytes of GVL undergo the process of activation, expansion and effector to remove leukemia cells, which has be-come an effective treatment for intermediate and high-risk hematologic diseases. The donor T lymphocytes of GVL undergo the process of activation, expansion and effector to remove leukemia cells, and become an effective treatment for medium and high-risk hematological diseases. T lym-phocytes are the main effector cells to exert the graft-versus-leukemia effect, and play an important role in post-transplantation infections, GVHD, and relapses. PD-1, TIM-3, LAG-3, and CD47 inhibit the T cells to exert the immune effect by different mechanisms, so the allogeneic hematopoietic stem cells can be used for the treatment of leukemia through different mechanisms. PD-1, TIM-3, LAG-3, and CD47 inhibit T cells from exerting immune effects through different mechanisms, so the study of the reconstruction pattern of T lymphocytes and the above mentioned immune checkpoints after allogeneic hematopoietic stem cell transplantation is of great significance for prognosis.
文章引用：李玉芳. 异基因造血干细胞移植后免疫重建的研究[J]. 临床医学进展, 2023, 13(12): 19206-19213. https://doi.org/10.12677/ACM.2023.13122703

参考文献

[1] Stern, L., McGuire, H., Avdic, S., et al. (2018) Mass Cytometry for the Assessment of Immune Reconstitution after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 9, Article No. 1672. [Google Scholar] [CrossRef] [PubMed]
[2] 刘洋. 异基因造血干细胞移植患者免疫细胞恢复监测及临床意义[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2015.
[3] 陈凯. 异基因造血干细胞移植后免疫重建的研究进展[J]. 国际儿科学杂志, 2020, 47(2): 96-99.
[4] Bishop, M.-R., Alyea, E.P.-Rd., Cairo, M.-S., et al. (2011) Na-tional Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Alloge-neic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 17, 443-454. [Google Scholar] [CrossRef] [PubMed]
[5] Strasfeld, L. (2022) COVID-19 and HSCT (Hematopoietic Stem Cell Transplant). Best Practice & Research Clinical Haematology, 35, Article ID: 101399. [Google Scholar] [CrossRef] [PubMed]
[6] Guo, W.-W., Liu, X., Pang, A.-M., et al. (2021) Analysis of Risk Factors of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with t (8;21) Acute Myeloid Leukemia. Chinese Journal of Hematology, 42, 998-1004.
[7] 刘建宁. PD-1、TIM-3、LAG-3在急性白血病异基因造血干细胞移植后T淋巴细胞的表达及意义初探[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2020.
[8] Takaku, S., Shimizu, M. and Morita, R. (2023) CD8(+) T Cell-Mediated Therapeutic Antitumor Effect of an Herbal Mixture Containing Ganoderma lucidum. Evidence-Based Complementary and Alternative Medicine, 2023, Arti-cle ID: 9630816. [Google Scholar] [CrossRef] [PubMed]
[9] Velardi, E., Tsai, J.-J. and van den Brink, M.R.M. (2021) T Cell Regeneration after Immunological Injury. Nature Reviews Immunology, 21, 277-291. [Google Scholar] [CrossRef] [PubMed]
[10] Omer, A.-K., Ziakas, P.-D., Anagnostou, T., et al. (2013) Risk Factors for Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experi-ence. Biology of Blood and Marrow Transplantation, 19, 1190-1196. [Google Scholar] [CrossRef] [PubMed]
[11] Seggewiss, R. and Einsele, H. (2010) Immune Reconstitution after Allogeneic Transplantation and Expanding Options for Immunomodulation: An Update. Blood, 115, 3861-3868. [Google Scholar] [CrossRef] [PubMed]
[12] van der Maas, N.-G., Berghuis, D., van der Burg, M., et al. (2019) B Cell Reconstitution and Influencing Factors after Hematopoietic Stem Cell Transplantation in Children. Fron-tiers in Immunology, 10, Article No. 782. [Google Scholar] [CrossRef] [PubMed]
[13] Stern, L., McGuire, H., Avdic, S., et al. (2018) Mass Cytometry for the Assessment of Immune Reconstitution after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 9, Article No. 1672. [Google Scholar] [CrossRef] [PubMed]
[14] Chamoun, K., Milton, D.-R., Ledesma, C., et al. (2019) Allogeneic Transplantation after Myeloablative Rituximab/BEAM+/− Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biology of Blood and Marrow Transplantation, 25, 1347-1354. [Google Scholar] [CrossRef] [PubMed]
[15] van der Maas, N.-G., Berghuis, D., van der Burg, M., et al. (2019) B Cell Reconstitution and Influencing Factors after Hematopoietic Stem Cell Transplantation in Children. Frontiers in Immunology, 10, Article No. 782. [Google Scholar] [CrossRef] [PubMed]
[16] Abdel-Azim, H., Elshoury, A., Mahadeo, K.-M., et al. (2017) Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Mat-uration Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution. Biology of Blood and Marrow Transplantation, 23, 1437-1446. [Google Scholar] [CrossRef] [PubMed]
[17] Kroger, N., Zagrivnaja, M., Schwartz, S., et al. (2006) Kinetics of Plasma-Cell Chimerism after Allogeneic Stem Cell Transplantation by Highly Sensitive Real-Time PCR Based on Se-quence Polymorphism and Its Value to Quantify Minimal Residual Disease in Patients with Multiple Myeloma. Experi-mental Hematology, 34, 688-694. [Google Scholar] [CrossRef] [PubMed]
[18] Abrahamsen, I.-W., Somme, S., Heldal, D., et al. (2005) Im-mune Reconstitution after Allogeneic Stem Cell Transplantation: The Impact of Stem Cell Source and Graft-versus-Host Disease. Haematologica, 90, 86-93.
[19] Gianchecchi, E., Delfino, D.-V. and Fierabracci, A. (2013) Recent Insights in-to the Role of the PD-1/PD-L1 Pathway in Immunological Tolerance and Autoimmunity. Autoimmunity Reviews, 12, 1091-1100. [Google Scholar] [CrossRef] [PubMed]
[20] 陈晓晨. PD-1和TIM-3在耗竭T细胞介导B系淋巴瘤免疫逃逸中的作用机制及临床应用研究[D]: [博士学位论文]. 苏州: 苏州大学, 2020.
[21] 刘建宁, 孙立, 牛志云, 等. PD-1在急性白血病异基因造血干细胞移植后T淋巴细胞的表达[J]. 临床荟萃, 2021, 36(3): 251-255.
[22] Simonetta, F., Pradier, A., Bosshard, C., et al. (2019) Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells after Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 10, Article No. 1034. [Google Scholar] [CrossRef] [PubMed]
[23] Michonneau, D., Sagoo, P., Breart, B., et al. (2016) The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity That Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation. Immunity, 44, 143-154. [Google Scholar] [CrossRef] [PubMed]
[24] Haverkos, B.-M., Abbott, D., Hamadani, M., et al. (2017) PD-1 Blockade for Relapsed Lymphoma Post-Allogeneic Hematopoietic Cell Transplant: High Response Rate but Frequent GVHD. Blood, 130, 221-228. [Google Scholar] [CrossRef] [PubMed]
[25] Monney, L., Sabatos, C.A., Gaglia, J.L., et al. (2002) Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease. Nature, 415, 536-541. [Google Scholar] [CrossRef] [PubMed]
[26] Acharya, N., Sabatos-Peyton, C. and Anderson, A.-C. (2020) Tim-3 Finds Its Place in the Cancer Immunotherapy Landscape. The Journal for ImmunoTherapy of Cancer, 8, e000911. [Google Scholar] [CrossRef] [PubMed]
[27] Kuai, W., Xu, X., Yan, J., et al. (2020) Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer. BioMed Research International, 2020, Article ID: 5294043. [Google Scholar] [CrossRef] [PubMed]
[28] Khalaf, S., Toor, S.-M., Murshed, K., et al. (2020) Differential Expres-sion of TIM-3 in Circulation and Tumor Microenvironment of Colorectal Cancer Patients. Clinical Immunology, 215, Ar-ticle ID: 108429. [Google Scholar] [CrossRef] [PubMed]
[29] Joller, N. and Kuchroo, V.-K. (2017) Tim-3, Lag-3, and TIGIT. In: Yoshimura, A., Ed., Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity, Vol. 410, Springer, Berlin, 127-156. [Google Scholar] [CrossRef] [PubMed]
[30] 田金, 张腾龙, 李玲, 等. LAG-3分子的研究进展[J]. 新医学, 2020, 51(9): 663-666.
[31] Sega, E.-I., Leveson-Gower, D.-B., Florek, M., et al. (2014) Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation. PLOS ONE, 9, e86551. [Google Scholar] [CrossRef] [PubMed]
[32] Brown, E.-J. and Frazier, W.-A. (2001) Integrin-Associated Protein (CD47) and Its Ligands. Trends in Cell Biology, 11, 130-135. [Google Scholar] [CrossRef] 
[33] 尹松梅, 康颖. CD47生理功能的研究[J]. 中国实验血液学杂志, 2003, 11(4): 437-440.
[34] 武倩, 周芳, 解琳娜, 等. allo-HSCT后急性GVHD患者外周血中T淋巴细胞CD47表达变化的观察[J]. 中华器官移植杂志, 2016, 37(5): 275-279.
[35] 黄盼盼, 张爱梅, 张翠萍, 等. 外周血干细胞移植与非血缘脐带血移植的患者免疫重建规律的比较[J]. 中华检验医学杂志, 2021, 44(12): 1138-1144.
[36] Hoffmeister, P.A., Storer, B.E., Macris, P.C., et al. (2013) Relationship of Body Mass Index and Arm Anthropometry to Outcomes after Pediatric Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 19, 1081-1086. [Google Scholar] [CrossRef] [PubMed]
[37] Hess, A.-D. (2010) Reconstitution of Self-Tolerance after Hema-topoietic Stem Cell Transplantation. Immunology Research, 47, 143-152. [Google Scholar] [CrossRef] [PubMed]
[38] Nakashima, A., Carrero, J.-J., Qureshi, A.-R., et al. (2010) Effect of Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) and the Proinflammatory RAGE Ligand (EN-RAGE, S100A12) on Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology, 5, 2213-2219. [Google Scholar] [CrossRef] 
[39] Ando, T., Tachibana, T., Tanaka, M., et al. (2020) Impact of Graft Sources on Immune Reconstitution and Survival Outcomes Following Allogeneic Stem Cell Transplantation. Blood Ad-vances, 4, 408-419. [Google Scholar] [CrossRef] [PubMed]
[40] Cham, L.-B., Torrez Dulgeroff, L.B., Tal, M.-C., et al. (2020) Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection. Cell Reports, 31, Article ID: 107494. [Google Scholar] [CrossRef] [PubMed]
[41] Annaloro, C., Serpenti, F., Saporiti, G., et al. (2020) Viral Infec-tions in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications. Frontiers in Immunology, 11, Article ID: 569381. [Google Scholar] [CrossRef] [PubMed]
[42] Miyashita, M., Shimizu, T., Ashihara, E., et al. (2021) Strategies to Improve the Antitumor Effect of Gammadelta T Cell Immunotherapy for Clinical Application. International Journal of Molecular Sciences, 22, Article No. 8910. [Google Scholar] [CrossRef] [PubMed]
[43] Ciceri, F., Bacigalupo, A., Lankester, A., et al. (2019) Haploidentical HSCT. In: Carreras, E., Dufour, C., Mohty, M. and Kröger, N., Eds., The EBMT Handbook, Springer, Berlin, 479-486. [Google Scholar] [CrossRef] 
[44] Storb, R. (2019) HSCT: Historical Perspective. In: Carreras, E., Dufour, C., Mohty, M. and Kröger, N., Eds., The EBMT Handbook, Springer, Berlin, 3-9. [Google Scholar] [CrossRef] 
[45] Reisner, Y. (2019) Haploidentical HSCT—Going from Strength to Strength. Bone Marrow Transplantation, 54, 687-688. [Google Scholar] [CrossRef] [PubMed]

为你推荐